Organization
Desert Medical Advances, Rheumatology, Palm Desert, United States of America
1 abstract
Abstract
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MGOrg: Oregon Health & Science University, Rheumatology, Portland, United States of America, Altoona Center for Clinical Research, Altoona Arthritis and Osteoporosis Center, Duncansville, United States of America, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Rheumatology, Cleveland, United States of America, University of Utah School of Medicine and Salt Lake City Veterans Affairs Medical Center, Rheumatology, Salt Lake City, United States of America, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America,